Argenx SE (NASDAQ:ARGX) ranks among the best high growth European stocks to buy. On January 12, William Blair maintained its Outperform rating on Argenx SE (NASDAQ:ARGX), citing robust sales growth in the company’s Vyvgart brand. The firm reports that Vyvgart sales stay ahead of expectations and demonstrate solid momentum, which it expects to last through 2026 across authorized applications in MG (myasthenia gravis) and CIDP. The firm also emphasized the potential of Argenx’s other clinical products, inc ...

The Carlyle Group Inc. (NASDAQ:CG) ranks among the best financial stocks to buy according to billionaire Israel Englander. On January 14, TD Cowen analyst Bill Katz cut his price target for The Carlyle Group Inc. (NASDAQ:CG) to $76 from $77, while maintaining a Buy rating. The firm’s position remains essentially positive on Traditional Asset Managers, though with a tighter concentration on higher-conviction ideas, while keeping an eye on Alternatives with a shift toward more “Higher for Longer” strategy an ...

Core Insights - Apellis Pharmaceuticals Inc. is considered one of the most oversold biotech stocks to invest in, with a Neutral rating maintained by Mizuho and a price target reduction from $24 to $19 [1] Financial Performance - In Q3 2025, Syfovre's revenue was $150.9 million, slightly down from $152.0 million in Q3 2024, but there was a 4% quarter-over-quarter increase in injections [2] - Apellis Pharmaceuticals reported that Syfovre holds over 60% market share in the geographic atrophy (GA) treatment area, with 52% of new patient starts in Q3 2025 [2] - Mizuho has lowered its revenue projections for Syfovre, now estimating a peak annual revenue of about $800 million, which is 25-30% lower than consensus estimates [2] Company Overview - Apellis Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutic compounds for diseases with high unmet needs [2]

Core Viewpoint - Churchill Downs Incorporated (NASDAQ:CHDN) is considered one of the most undervalued stocks on NASDAQ, with a current trading multiple of 9.4x expected EBITDA for 2027, below its long-term average of 11.7x, indicating potential for price appreciation [1]. Group 1: Investment Outlook - JMP Securities has reiterated a Market Outperform rating for Churchill Downs with a price target of $142, reflecting confidence in the company's growth prospects [1]. - The firm has identified several potential triggers for stock performance leading up to the 2026 Kentucky Derby, including historical racing machines (HRMs), financing decisions, and expected return on invested capital (ROIC) [2]. Group 2: Business Segments - Churchill Downs operates in the gambling sector, providing online betting, gaming, and racing services, and is structured into three main divisions: live and historical racing, wagering services, and gaming [3].